The in vivo systemic effect of human recombinant interleukin-1 beta on fibronectin in rats.
The in vivo systemic effect of interleukin (IL)-1 beta on plasma and cartilage fibronectin was studied in arthritic rats, as well as alpha 1-acid glycoprotein and albumin. Plasma fibronectin showed a 27% increase in the arthritic group, while alpha 1-acid glycoprotein increased 22-fold and albumin decreased by 46%. IL-1 effect depended on the administered dose. 2 micrograms injection significantly increased plasma fibronectin and alpha 1-acid glycoprotein. In cartilage, fibronectin was significantly modified in arthritic animals but increased in a dose-related manner after IL-1 treatment. As IL-1 increases fibronectin-degrading enzyme production and as some of these fragments can develop properties that do not possess the intact molecule, one can postulate a vicious circle in matrix degradation in the inflammatory process of the joint.
Feng
X Z
XZ
Laboratoire de Biochimie du tissu conjonctif, URA CNRS 1460 Faculté de Médecine, Créteil, France.
Jouzeau
J Y
JY
Durand
G
G
Netter
P
P
Labat-Robert
J
J
D000818:Animals; D001169:Arthritis, Experimental / Q000378:metabolism*; D002356:Cartilage / Q000187:drug effects / Q000378:metabolism*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005353:Fibronectins / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D009961:Orosomucoid / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D011920:Rats, Inbred WF; D011994:Recombinant Proteins / Q000494:pharmacology; D012709:Serum Albumin / Q000032:analysis
D005353:Fibronectins; D007375:Interleukin-1; D009961:Orosomucoid; D011994:Recombinant Proteins; D012709:Serum Albumin